Valneva (NASDAQ:VALN – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Valneva to similar businesses based on the strength of its profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Analyst Ratings
This is a breakdown of recent ratings for Valneva and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valneva | 2 | 0 | 1 | 0 | 1.67 |
| Valneva Competitors | 9941 | 15328 | 45742 | 1605 | 2.54 |
Valneva currently has a consensus price target of $9.30, suggesting a potential upside of 67.12%. As a group, “Biotechnology” companies have a potential upside of 133.48%. Given Valneva’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Valneva has less favorable growth aspects than its rivals.
Risk & Volatility
Institutional and Insider Ownership
11.4% of Valneva shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Valneva and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Valneva | $197.56 million | -$130.33 million | -2.64 |
| Valneva Competitors | $688.58 million | $7.69 million | -18.30 |
Valneva’s rivals have higher revenue and earnings than Valneva. Valneva is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Valneva and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Valneva | -110.33% | -153.20% | -39.50% |
| Valneva Competitors | -12,224.75% | -204.85% | -31.52% |
Summary
Valneva rivals beat Valneva on 8 of the 13 factors compared.
About Valneva
Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
